Correlation Engine 2.0
Clear Search sequence regions


  • cataracts (9)
  • connexin (5)
  • diagnosis (2)
  • factors (2)
  • GSH (6)
  • gsh transport (1)
  • humans (1)
  • lipid (2)
  • malondialdehyde (2)
  • pathogenesis (3)
  • SOD1 (1)
  • therapies (1)
  • Sizes of these terms reflect their relevance to your search.

    Oxidative stress plays a central role in cataract pathogenesis, a leading cause of global blindness. This review delves into the role of oxidative stress in cataract development and key biomarkers - glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE) - to clarify their functions and potential applications in predictive diagnostics and therapies. Antioxidants serve as pivotal markers in cataract pathogenesis. GSH affects the central lens due to factors such as enzyme depletion and altered connexin expression, impairing GSH diffusion. Age-related oxidative stress may hinder GSH transport via connexin channels or an internal microcirculation system. N-acetylcysteine, a GSH precursor, shows promise in mitigating lens opacity when applied topically. Additionally, SOD, particularly SOD1, correlates with increased cataract development and gel formulations have exhibited protective effects against posterior subscapular cataracts. Lastly, markers of lipid peroxidation, MDA and 4-HNE, have been shown to reflect disease severity. Studies suggest a potential link between 4-HNE and connexin channel modification, possibly contributing to reduced GSH levels. Oxidative stress is a significant contributor to cataract development, underscoring the importance of antioxidants in diagnosis and treatment. Notably, GSH depletion, SOD decline, and lipid peroxidation markers are pivotal factors in cataract pathogenesis, offering promising avenues for both diagnosis and therapeutic intervention. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

    Citation

    Bryanna Lee, Natalie A Afshari, Peter X Shaw. Oxidative stress and antioxidants in cataract development. Current opinion in ophthalmology. 2024 Jan 01;35(1):57-63

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37882550

    View Full Text